Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 11Cyclophosphamide 10Biological Therapy 9Drug Therapy 8Dexamethasone 7Biopsy 7antineoplaston A10 6Nivolumab 6Complementary Therapies 6fludarabine 5antineoplaston AS 2-1 5aldesleukin 5Ipilimumab 5Etoposide 5Doxorubicin 5Cisplatin 5atezolizumab 4Vincristine 4Surgical Procedures, Operative 4Rituximab 4Paclitaxel 4Chemotherapy, Adjuvant 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4venetoclax 3olaparib 3dexamethasone acetate 3dexamethasone 21-phosphate 3copanlisib 3auricularum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × NIH × Homoharringtonine × Clear all
NCT00030355 2013-03-22

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡